Skip to main content

Articles

Page 1 of 31

  1. Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To d...

    Authors: Angel Y. S. Wong, Laurie A. Tomlinson, Jeremy P. Brown, William Elson, Alex J. Walker, Anna Schultze, Caroline E. Morton, David Evans, Peter Inglesby, Brian MacKenna, Krishnan Bhaskaran, Christopher T. Rentsch, Emma Powell, Elizabeth Williamson, Richard Croker, Seb Bacon…

    Citation: Journal of Hematology & Oncology 2021 14:172

    Content type: Research

    Published on:

  2. GTPase-activating protein (GAP) is a negative regulator of GTPase protein that is thought to promote the conversion of the active GTPase-GTP form to the GTPase-GDP form. Based on its ability to regulate GTPase...

    Authors: Hua He, Jingjing Huang, Sufang Wu, Shiyao Jiang, Lu Liang, Yueying Liu, Wenbing Liu, Li Xie, Yongguang Tao, Yiqun Jiang and Li Cong

    Citation: Journal of Hematology & Oncology 2021 14:171

    Content type: Review

    Published on:

  3. Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell an...

    Authors: Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A. Zhan, Maysun M. Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, Joseph M. Chan, Metamia Ciampricotti, Andrew Chow, Michael Offin, Jordana Ray-Kirton, Jacklynn D. Egger…

    Citation: Journal of Hematology & Oncology 2021 14:170

    Content type: Research

    Published on:

  4. Altered metabolic patterns in tumor cells not only meet their own growth requirements but also shape an immunosuppressive microenvironment through multiple mechanisms. Noncoding RNAs constitute approximately 6...

    Authors: Yiyin Zhang, Qijiang Mao, Qiming Xia, Jiaxi Cheng, Zhengze Huang, Yirun Li, Peng Chen, Jing Yang, Xiaoxiao Fan, Yuelong Liang and Hui Lin

    Citation: Journal of Hematology & Oncology 2021 14:169

    Content type: Review

    Published on:

  5. Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management ...

    Authors: Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Luisa Verga, Benjamin Víšek, Osman Ilhan, Gianpaolo Nadali, Barbora Weinbergerová, Raúl Córdoba-Mascuñano…

    Citation: Journal of Hematology & Oncology 2021 14:168

    Content type: Research

    Published on:

  6. Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, ...

    Authors: Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang…

    Citation: Journal of Hematology & Oncology 2021 14:167

    Content type: Letter to the Editor

    Published on:

  7. Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to e...

    Authors: Samuel Bitoun, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, Delphine Desjardins, Marie Bitu, Roger Le Grand, Raphaèle Seror, Anne-Marie Roque Afonso and Xavier Mariette

    Citation: Journal of Hematology & Oncology 2021 14:166

    Content type: Letter to the Editor

    Published on:

  8. Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging....

    Authors: Lei Liang, Chao Li, Ming-Da Wang, Hong Wang, Ya-Hao Zhou, Yong-Yi Zeng, Wan-Guang Zhang, Ting-Hao Chen, Nan-Ya Wang, Jie Li, Yao-Ming Zhang, Yu Wang, Wei-Min Gu, Hao Xing, Yong-Kang Diao, Wan Yee Lau…

    Citation: Journal of Hematology & Oncology 2021 14:165

    Content type: Letter to the Editor

    Published on:

  9. Peritoneal dissemination (PD) is a major type of gastric cancer (GC) recurrence and leads to rapid death. Current approaches cannot precisely determine which patients are at high risk of PD to provide early in...

    Authors: Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang and Yuchen Jiao

    Citation: Journal of Hematology & Oncology 2021 14:164

    Content type: Letter to the Editor

    Published on:

  10. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, ...

    Authors: Jadwiga Węcławek-Tompol, Zuzanna Zakrzewska, Olga Gryniewicz-Kwiatkowska, Filip Pierlejewski, Ewa Bień, Agnieszka Zaucha-Prażmo, Olga Zając-Spychała, Anna Szmydki-Baran, Agnieszka Mizia-Malarz, Wioletta Bal, Małgorzata Sawicka-Żukowska, Agnieszka Kruk, Anna Raciborska, Agnieszka Książek, Tomasz Szczepański, Jarosław Peregud-Pogorzelski…

    Citation: Journal of Hematology & Oncology 2021 14:163

    Content type: Research

    Published on:

  11. CAR T cell therapy has shown dramatic clinical success in relapsed or refractory B-ALL and other hematological malignancies. However, the loss of specific antigens, cell fratricide, T cell aplasia, and normal ...

    Authors: Jiangzhou Shi, Zijian Zhang, Hong Cen, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin…

    Citation: Journal of Hematology & Oncology 2021 14:162

    Content type: Letter to the Editor

    Published on:

  12. BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target i...

    Authors: Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng…

    Citation: Journal of Hematology & Oncology 2021 14:161

    Content type: Research

    Published on:

  13. In this era of precision medicine, with the help of biomarkers, immunotherapy has significantly improved prognosis of many patients with malignant tumor. Deficient mismatch repair (dMMR)/microsatellite instabi...

    Authors: Wantao Wu, Yihan Liu, Shan Zeng, Ying Han and Hong Shen

    Citation: Journal of Hematology & Oncology 2021 14:160

    Content type: Review

    Published on:

  14. New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage rel...

    Authors: Kevin Marquant, Anne Quinquenel, Carl Arndt and Alexandre Denoyer

    Citation: Journal of Hematology & Oncology 2021 14:159

    Content type: Case report

    Published on:

  15. Authors: Zhaojin Yu, Wensi Liu, Ying He, Mingli Sun, Jiankun Yu, Xue Jiao, Qiang Han, Haichao Tang, Bing Zhang, Yunkai Xian, Jing Qi, Jing Gong, Wang Xin, Gang Shi, Fengping Shan, Rui Zhang…

    Citation: Journal of Hematology & Oncology 2021 14:158

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:71

  16. TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. ...

    Authors: Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liuxin Cai, Xiujun Cai and Mingyu Chen

    Citation: Journal of Hematology & Oncology 2021 14:157

    Content type: Review

    Published on:

  17. Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, ...

    Authors: Shaoming Zhu, Tian Zhang, Lei Zheng, Hongtao Liu, Wenru Song, Delong Liu, Zihai Li and Chong-xian Pan

    Citation: Journal of Hematology & Oncology 2021 14:156

    Content type: Review

    Published on:

  18. Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting wit...

    Authors: Siret Tahk, Binje Vick, Björn Hiller, Saskia Schmitt, Anetta Marcinek, Enrico D. Perini, Alexandra Leutbecher, Christian Augsberger, Anna Reischer, Benjamin Tast, Andreas Humpe, Irmela Jeremias, Marion Subklewe, Nadja C. Fenn and Karl-Peter Hopfner

    Citation: Journal of Hematology & Oncology 2021 14:155

    Content type: Research

    Published on:

  19. Liver cancer remains the leading cause of cancer death globally, and the treatment strategies are distinct for each type of malignant hepatic tumors. However, the differential diagnosis before surgery is chall...

    Authors: Ruitian Gao, Shuai Zhao, Kedeerya Aishanjiang, Hao Cai, Ting Wei, Yichi Zhang, Zhikun Liu, Jie Zhou, Bing Han, Jian Wang, Han Ding, Yingbin Liu, Xiao Xu, Zhangsheng Yu and Jinyang Gu

    Citation: Journal of Hematology & Oncology 2021 14:154

    Content type: Letter to the Editor

    Published on:

  20. The 3-hydroxyanthranilic acid (3-HAA), a derivative of kynurenine, was reported to suppress tumor growth. However, the function of 3-HAA largely remains unclear. Here, we report that 3-hydroxyanthranilic acid ...

    Authors: Zhaopeng Shi, Guifang Gan, Xiang Xu, Jieying Zhang, Yuan Yuan, Bo Bi, Xianfu Gao, Pengfei Xu, Wenbin Zeng, Jixi Li, Youqiong Ye, Aiwu Zhou, Naixia Zhang, Wen Liu, Shuhai Lin and Jun Mi

    Citation: Journal of Hematology & Oncology 2021 14:153

    Content type: Letter to the Editor

    Published on:

  21. Chimeric antigen receptor T-cell (CAR-T) therapy has shown tremendous success in eradicating hematologic malignancies. However, this success has not yet been extrapolated to solid tumors due to the limited inf...

    Authors: Feng Ji, Fan Zhang, Miaomiao Zhang, Kaili Long, Mingyue Xia, Fei Lu, Enjie Li, Jiannan Chen, Jun Li, Zhengliang Chen, Li Jing, Shaochang Jia, Rong Yang, Zhigang Hu and Zhigang Guo

    Citation: Journal of Hematology & Oncology 2021 14:152

    Content type: Letter to the Editor

    Published on:

  22. New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individ...

    Authors: Craig T. Wallington-Beddoe and Rachel L. Mynott

    Citation: Journal of Hematology & Oncology 2021 14:151

    Content type: Review

    Published on:

  23. Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie and Weidong Han

    Citation: Journal of Hematology & Oncology 2021 14:150

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:106

  24. CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To impro...

    Authors: Guoling Wang, Xiaolei Sun, Shiyu Zuo, Chuo Li, Qing Niu, Yonghui Xia, Yuan Meng, Min Liu, Zihao Fang, Xi Yang, Yanyu Jiang, Sheng Wang, Haidong Cui, Huifang Huang, Erlie Jiang, Dongming Zhou…

    Citation: Journal of Hematology & Oncology 2021 14:149

    Content type: Letter to the Editor

    Published on:

  25. Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism an...

    Authors: Jin-Woo Lee, Jin Hur, Yoo-Wook Kwon, Cheong-Whan Chae, Jae-Il Choi, Injoo Hwang, Ji-Yeon Yun, Jin-A Kang, Young-Eun Choi, Young Hyun Kim, Sang Eun Lee, Cheol Lee, Dong Hyun Jo, Heeyoung Seok, Byong Seung Cho, Sung Hee Baek…

    Citation: Journal of Hematology & Oncology 2021 14:148

    Content type: Research

    Published on:

  26. Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death protein 1/programmed cell death l...

    Authors: Wenjing Qian, Mingfang Zhao, Ruoyu Wang and Heming Li

    Citation: Journal of Hematology & Oncology 2021 14:147

    Content type: Review

    Published on:

  27. Our previous work showed that the anti-TGF-β/PD-L1 bispecific antibody YM101 effectively overcame anti-PD-L1 resistance in immune-excluded tumor models. However, in immune-desert models, the efficacy of YM101 ...

    Authors: Ming Yi, Mengke Niu, Jing Zhang, Shiyu Li, Shuangli Zhu, Yongxiang Yan, Ning Li, Pengfei Zhou, Qian Chu and Kongming Wu

    Citation: Journal of Hematology & Oncology 2021 14:146

    Content type: Research

    Published on:

  28. The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

    Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…

    Citation: Journal of Hematology & Oncology 2021 14:145

    Content type: Review

    Published on:

  29. Malignant adenomyoepithelioma (AME) of the breast is an exceptionally rare form of breast cancer, with a significant metastatic potential. Chemotherapy has been used in the management of advanced AME patients,...

    Authors: Ivan Bièche, Florence Coussy, Rania El-Botty, Sophie Vacher, Sophie Château-Joubert, Ahmed Dahmani, Elodie Montaudon, Cécile Reyes, David Gentien, Fabien Reyal, Francesco Ricci, André Nicolas, Caterina Marchio, Anne Vincent-Salomon, Marick Laé and Elisabetta Marangoni

    Citation: Journal of Hematology & Oncology 2021 14:143

    Content type: Letter to the Editor

    Published on:

  30. Tumor microenvironment (TME) is a dynamic cellular milieu to promote tumor angiogenesis, growth, proliferation, and metastasis, while derailing the host anti-tumor response. TME impedes bispecific antibody (Bs...

    Authors: Jeong A. Park, Linlin Wang and Nai-Kong V. Cheung

    Citation: Journal of Hematology & Oncology 2021 14:142

    Content type: Research

    Published on:

  31. Pancreatic cancer has the worst prognosis among common tumors which is attributed to its aggressive phenotype, diagnosis at advanced, inoperable stages, and resistance to systemic therapy. Non-coding RNAs (ncR...

    Authors: Moritz Reese and Sameer A. Dhayat

    Citation: Journal of Hematology & Oncology 2021 14:141

    Content type: Review

    Published on:

  32. In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety...

    Authors: David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox and Guillaume Cartron

    Citation: Journal of Hematology & Oncology 2021 14:140

    Content type: Research

    Published on:

  33. The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the wide applicati...

    Authors: Guoyun Jiang, Zhenglan Huang, Ying Yuan, Kun Tao and Wenli Feng

    Citation: Journal of Hematology & Oncology 2021 14:139

    Content type: Research

    Published on:

  34. Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due ...

    Authors: Haobin Li, Jinyun Dong, Maohua Cai, Zhiyuan Xu, Xiang-Dong Cheng and Jiang-Jiang Qin

    Citation: Journal of Hematology & Oncology 2021 14:138

    Content type: Review

    Published on:

  35. Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and ap...

    Authors: Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel and Nicholas J. Short

    Citation: Journal of Hematology & Oncology 2021 14:137

    Content type: Review

    Published on:

  36. Extracellular vesicles (EVs) are cell-derived membrane structures enclosing proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs have emerged as essential intercellular communication regulat...

    Authors: Zhijie Weng, Bowen Zhang, Chenzhou Wu, Fanyuan Yu, Bo Han, Bo Li and Longjiang Li

    Citation: Journal of Hematology & Oncology 2021 14:136

    Content type: Review

    Published on:

  37. Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-0...

    Authors: Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy Chevassut, Francesca Pierdomenico…

    Citation: Journal of Hematology & Oncology 2021 14:133

    Content type: Research

    Published on:

  38. Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-app...

    Authors: Vivian Changying Jiang, Yang Liu, Alexa Jordan, Joseph McIntosh, Yijing Li, Yuxuan Che, Katti A. Jessen, Brian J. Lannutti and Michael Wang

    Citation: Journal of Hematology & Oncology 2021 14:132

    Content type: Letter to the Editor

    Published on:

  39. Clinical features and outcomes of FL patients in Chinese population are limited, thus promoting us to perform this analysis on a large cohort of 1845 patients with FL enrolled from nine medical centers nationw...

    Authors: Jie Zha, Liyuan Fan, Shuhua Yi, Haifeng Yu, Zhong Zheng, Wei Xu, Manman Deng, Zhijuan Lin, Zhifeng Li, Lingyan Ping, Xiaohua He, Feili Chen, Ying Xie, Biyun Chen, Huilai Zhang, Li Wang…

    Citation: Journal of Hematology & Oncology 2021 14:131

    Content type: Letter to the Editor

    Published on:

  40. YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patie...

    Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu and Lugui Qiu

    Citation: Journal of Hematology & Oncology 2021 14:130

    Content type: Letter to the Editor

    Published on:

  41. METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (H...

    Authors: Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez and Chukwuemeka V. Ikpeazu

    Citation: Journal of Hematology & Oncology 2021 14:129

    Content type: Review

    Published on:

  42. Biomarkers-guided precision therapeutics has revolutionized the clinical development and administration of molecular-targeted anticancer agents. Tailored precision cancer therapy exhibits better response rate ...

    Authors: Hui Hua, Hongying Zhang, Jingzhu Chen, Jiao Wang, Jieya Liu and Yangfu Jiang

    Citation: Journal of Hematology & Oncology 2021 14:128

    Content type: Review

    Published on:

  43. The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.

    Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2021 14:127

    Content type: Research

    Published on:

  44. The assessment of measurable residual disease (MRD) in bone marrow has proven of prognostic relevance in patients with multiple myeloma (MM). Nevertheless, and unlike other hematologic malignancies, the use of...

    Authors: Joaquin Martinez-Lopez, Rafael Alonso, Sandy W. Wong, Rafael Rios, Nina Shah, Yanira Ruiz-Heredia, Jose Maria Sanchez-Pina, Ricardo Sanchez, Natasha Bahri, Irene Zamanillo, Maria Poza, Natalia Buenache, Cristina Encinas, Luis Juarez, Fatima Miras, Luis Collado…

    Citation: Journal of Hematology & Oncology 2021 14:126

    Content type: Letter to the Editor

    Published on:

  45. The bispecific antibody (bsAbs) research around the world has undergone great changes. We analyzed the global trend of bsAbs research and compared the differences in clinical research of bsAbs between China an...

    Authors: Zhonghan Zhang, Fan Luo, Jiaxin Cao, Feiteng Lu, Yang Zhang, Yuxiang Ma, Kangmei Zeng, Li Zhang and Hongyun Zhao

    Citation: Journal of Hematology & Oncology 2021 14:124

    Content type: Letter to the Editor

    Published on:

  46. Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by...

    Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…

    Citation: Journal of Hematology & Oncology 2021 14:123

    Content type: Letter to the Editor

    Published on:

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here